About Taysha Gene Therapies, Inc.
https://www.tayshagtx.comTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
CEO
Sean P. Nolan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 113
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Chardan Capital
Buy
Needham
Buy
Canaccord Genuity
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:24.35M
Value:$122.75M
RA CAPITAL MANAGEMENT, L.P.
Shares:23.56M
Value:$118.72M
AVORO CAPITAL ADVISORS LLC
Shares:21.7M
Value:$109.37M
Summary
Showing Top 3 of 162
About Taysha Gene Therapies, Inc.
https://www.tayshagtx.comTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $33.74M ▲ | $-32.73M ▼ | 0% ▲ | $-0.09 ▼ | $-32.43M ▼ |
| Q2-2025 | $1.99M ▼ | $28.74M ▲ | $-26.88M ▼ | -1.35K% ▼ | $-0.09 ▼ | $-26.59M ▼ |
| Q1-2025 | $2.3M ▲ | $23.72M ▲ | $-21.53M ▼ | -935.23% ▼ | $-0.08 ▲ | $-21.23M ▼ |
| Q4-2024 | $2.02M ▲ | $21.95M ▼ | $-18.79M ▲ | -929.03% ▲ | $-0.09 ▲ | $-18.46M ▲ |
| Q3-2024 | $1.79M | $27.69M | $-25.52M | -1.43K% | $-0.1 | $-25.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $297.34M ▼ | $316.55M ▼ | $97.56M ▲ | $218.99M ▼ |
| Q2-2025 | $312.76M ▲ | $333.33M ▲ | $84.6M ▲ | $248.73M ▲ |
| Q1-2025 | $116.59M ▼ | $138.36M ▼ | $83.3M ▼ | $55.06M ▼ |
| Q4-2024 | $139.04M ▼ | $160.36M ▼ | $88.84M ▼ | $71.53M ▼ |
| Q3-2024 | $157.69M | $180.22M | $91.42M | $88.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-32.73M ▼ | $-24.17M ▼ | $-48K ▼ | $8.8M ▼ | $-15.42M ▼ | $-24.27M ▼ |
| Q2-2025 | $-26.88M ▼ | $-20.18M ▲ | $62K ▲ | $216.29M ▲ | $196.17M ▲ | $-20.18M ▲ |
| Q1-2025 | $-21.53M ▼ | $-22.02M ▼ | $-371K ▼ | $-52K ▲ | $-22.44M ▼ | $-22.4M ▼ |
| Q4-2024 | $-18.79M ▲ | $-18.31M ▲ | $13K ▲ | $-357K ▼ | $-18.65M ▼ | $-18.31M ▲ |
| Q3-2024 | $-25.52M | $-21.61M | $-35K | $6.59M | $-15.05M | $-21.65M |
CEO
Sean P. Nolan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 113
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Chardan Capital
Buy
Needham
Buy
Canaccord Genuity
Buy
Citizens
Market Outperform
JMP Securities
Market Outperform
Baird
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
RTW INVESTMENTS, LP
Shares:24.35M
Value:$122.75M
RA CAPITAL MANAGEMENT, L.P.
Shares:23.56M
Value:$118.72M
AVORO CAPITAL ADVISORS LLC
Shares:21.7M
Value:$109.37M
Summary
Showing Top 3 of 162